EDIT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

8.45M

-72.38%

-0.215

-60.92%

1.38M

-70.4%

-0.341

-62.97%

6.21M

+73.62%

-0.249

-22.48%

Estimates Revision

The market is revising No Change the revenue expectations for Editas Medicine, Inc. (EDIT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -47.55%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-47.55%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast EDIT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDIT is 4.02 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

4.02

High

5.00

Current: 0.000

Low

3.00

Averages

4.02

High

5.00

Chardan

Buy

downgrade

$12

2025-11-12

Reason

Chardan

Price Target

$12

2025-11-12

downgrade

Buy

Reason

Chardan lowered the firm's price target on Editas Medicine to $3.50 from $12 and keeps a Buy rating on the shares. The firm updated its Editas model for Q3 results and progress on lead in vivo gen editing candidate EDIT-401. The firm noted the space's pullback has created a buying opportunity.

Clear Street

Buy

maintain

2025-11-10

Reason

Clear Street

Price Target

2025-11-10

maintain

Buy

Reason

Clear Street raised the firm's price target on Editas Medicine to $4.60 from $4 and keeps a Buy rating on the shares following the Q3 report. The company maintained previously stated timelines for EDIT-401, the analyst tells investors in a research note. The firm sees $1.8B in peak sales and a 10% likelihood of success.

Wells Fargo

Equal Weight

maintain

$3 -> $4

2025-09-03

Reason

Wells Fargo

Price Target

$3 -> $4

2025-09-03

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Editas Medicine to $4 from $3 and keeps an Equal Weight rating on the shares. The firm thinks the LDLR upregulation mechanism leveraged by EDIT-401 is intriguing, with the promise of a potent new approach to lower LDL-C. Wells does think initial derisking on the safety of this new approach would be helpful and awaits updates on IND in 2026.

H.C. Wainwright

Buy

upgrade

$3 -> $5

2025-08-15

Reason

H.C. Wainwright

Price Target

$3 -> $5

2025-08-15

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Editas Medicine to $5 from $3 and keeps a Buy rating on the shares following the Q2 report. The firm cites a more favorable expense trajectory for the target increase.

Baird

Outperform

maintain

$4 -> $6

2025-08-13

Reason

Baird

Price Target

$4 -> $6

2025-08-13

maintain

Outperform

Reason

Baird raised the firm's price target on Editas Medicine to $6 from $4 and keeps an Outperform rating on the shares. The company's Q2 results were inline with expectations as it continues to advance its in vivo editing programs, the analyst tells investors in a research note. The firm believes the announcement of a lead candidate in September could drive interest in the shares.

Baird

Outperform -> NULL

downgrade

$8 -> $4

2025-05-13

Reason

Baird

Price Target

$8 -> $4

2025-05-13

downgrade

Outperform -> NULL

Reason

Baird lowered the firm's price target on Editas Medicine to $4 from $8 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where its IP update provided incremental newsflow.

Valuation Metrics

The current forward P/E ratio for Editas Medicine Inc (EDIT.O) is -1.78, compared to its 5-year average forward P/E of -5.16. For a more detailed relative valuation and DCF analysis to assess Editas Medicine Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.16

Current PE

-1.78

Overvalued PE

-0.16

Undervalued PE

-10.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.81

Current EV/EBITDA

-0.48

Overvalued EV/EBITDA

1.42

Undervalued EV/EBITDA

-7.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

56.87

Current PS

11.01

Overvalued PS

120.01

Undervalued PS

-6.28

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 500.44% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

EDIT News & Events

Events Timeline

No data

News

3.0

2025-11-18NASDAQ.COM

Three Genomics Stocks Worth Adding to Your Portfolio

9.5

2025-11-07NASDAQ.COM

Janux Therapeutics, Inc. (JANX) Announces Q3 Loss but Exceeds Revenue Projections

9.0

2025-10-31SeekingAlpha

Gene Editing Therapy Firms Surge Following News of Simplified FDA Approval Process

People Also Watch

Frequently Asked Questions

What is Editas Medicine Inc (EDIT) stock price today?

The current price of EDIT is 2.14 USD — it has decreased -0.93 % in the last trading day.

What is Editas Medicine Inc (EDIT)'s business?

Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

What is the price predicton of EDIT Stock?

What is Editas Medicine Inc (EDIT)'s revenue for the last quarter?

Editas Medicine Inc revenue for the last quarter amounts to 7.54M USD, increased 12265.57 % YoY.

What is Editas Medicine Inc (EDIT)'s earnings per share (EPS) for the last quarter?

Editas Medicine Inc. EPS for the last quarter amounts to -0.28 USD, decreased -62.67 % YoY.

What changes have occurred in the market's expectations for Editas Medicine Inc (EDIT)'s fundamentals?

How many employees does Editas Medicine Inc (EDIT). have?

Editas Medicine Inc (EDIT) has 246 emplpoyees as of January 09 2026.

What is Editas Medicine Inc (EDIT) market cap?

Today EDIT has the market capitalization of 208.90M USD.